Analysts think SLRX stock price could increase by 629%
Jun 14, 2024, 6:28 AM
0.00%
What does SLRX do
Salarius Pharmaceuticals, a clinical-stage oncology company based in Houston, Texas, specializes in developing treatments for cancers with significant unmet medical needs, focusing on dysregulated gene expression. The company, which went public in 2015, is advancing a pipeline that includes SP-3164, a molecular glue, and seclidemstat (SP-2577), an LSD1 inhibitor targeting pediatric cancers and sarcomas.
3 analysts think SLRX stock price will increase by 628.73%. The current median analyst target is $3.31 compared to a current stock price of $0.45. The lowest analysts target is $3.28 and the highest analyst target is $3.41.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
